
The Scottish Medicines Consortium (SMC) has approved Otsuka’s Jinarc for the treatment of the genetic kidney disease autosomal dominant polycystic …

NICE has released final guidance recommending Otsuka’s Jinarc, the first-ever treatment shown to slow progression of life-threatening Autosomal Dominant Polycystic …
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations

